News tagged with buprenorphine
Buprenorphine (sold under the trade-names of Subutex, Suboxone (buprenorphine with naloxone) - high-dose tablets used for the treatment of addiction - Temgesic, Buprenex - solutions for injection used for acute pain in primary-care settings - Norspan and Butrans - transdermal preparations used for chronic pain) is a semi-synthetic opioid that is used to treat opioid addiction in higher dosages (>2 mg), to control moderate acute pain in non-opioid tolerant individuals in lower dosages (~200 µg), and to control moderate chronic pain in dosages ranging from 20-70 µg/hour.
Buprenorphine is one of the Bentley compounds derived from an alkaloid of the plant Papaver somniferum (the opium poppy), known as thebaine.
Buprenorphine has an extremely high binding affinity at the µ- and κ-opioid receptor. It has partial agonist activity at the µ-opioid receptor, partial or full agonist activity at the ORL1/nociceptin and δ-opioid receptor, and competitive antagonist activity at the κ-opioid receptor.
Buprenorphine hydrochloride was first marketed in the 1980s by Reckitt & Colman (now Reckitt Benckiser) as an analgesic, available generally as Temgesic 0.2 mg sublingual tablets, and as Buprenex in a 0.3 mg/ml injectable formulation. In October 2002, the Food and Drug Administration (FDA) of the United States additionally approved Suboxone and Subutex, buprenorphine's high-dose sublingual pill preparations indicated for detoxification and long-term replacement therapy in opioid dependency, and the drug is now used predominantly for this purpose.
In the European Union, Suboxone and Subutex, buprenorphine's high-dose sublingual tablet preparations, were approved for opioid addiction treatment in September 2006. In the Netherlands, Buprenorphine is a List II drug of the Opium Law, though special rules and guidelines apply to its prescription and dispensation. In the USA, it has been a Schedule III drug under the United Nations' Convention on Psychotropic Substances since it was rescheduled from Schedule V just before FDA approval of Suboxone and Subutex. In recent years, buprenorphine has been introduced in most European countries as a transdermal formulation for the treatment of chronic pain.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Among infants with neonatal abstinence syndrome (NAS; caused by in utero opioid exposure), variants in certain genes were associated with a shorter length of hospital stay and less need for treatment, preliminary findings ...
Diseases, Conditions, Syndromes Apr 30, 2013 | not rated yet | 0
(Medical Xpress)—In a surprise finding, Yale researchers report that adding cognitive behavioral therapy to the most commonly used drug treatment for opioid dependence does not further reduce illicit drug ...
Psychology & Psychiatry Jan 04, 2013 | 5 / 5 (1) | 0 |
(Medical Xpress)—People who inject drugs (PWID) can significantly reduce their risk of HIV infection with the use of opiate substitution treatments such as methadone, as suggested by an international team ...
HIV & AIDS Oct 05, 2012 | not rated yet | 0
(HealthDay) -- Heroin addicts often have an increased sensitivity to pain, and this sensitivity does not subside over the course of treatment with methadone or other opioids, new research finds.
Addiction Apr 25, 2012 | not rated yet | 1
Individuals addicted to prescription painkillers are more likely to succeed in treatment with the aid of the medication buprenorphine-naloxone (Suboxone), report McLean Hospital and Harvard Medical School researchers in today's ...
Medications Nov 07, 2011 | not rated yet | 1
Ordinary painkillers such as paracetamol may work better than the risky antipyschotic drugs often prescribed to calm agitation in people with dementia, according to a study released Monday.
Diseases, Conditions, Syndromes Jul 18, 2011 | 4 / 5 (1) | 0
Children prenatally exposed to methadone or Subutex (buprenorphine) are prone to developing cognitive difficulties. According to one researcher, these children still need close follow-up after they begin ...
Psychology & Psychiatry Apr 16, 2013 | 5 / 5 (1) | 0
In what is believed to be the first study of its kind to demonstrate an association between the antidepressant escitalopram and improved general pain, researchers from Boston University School of Medicine (BUSM), have found ...
Medical research Nov 03, 2011 | 5 / 5 (1) | 0
Many health care professionals (HCPs) have easy access to controlled medications and the diversion and abuse of drugs among this group may be as high as 10%. Controversy surrounds the safety of allowing addicted HCPs to return ...
Addiction Mar 02, 2012 | not rated yet | 0
Buprenorphine is a safe and effective drug for treating opioid addiction. But as the prescribed use of buprenorphine has dramatically increased in recent years, accidental exposure of children to the drug has risen sharply, ...
Medications Dec 14, 2012 | not rated yet | 0